Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comprehensive, Individualized, Person-Centered Management of Community-Residing Persons with Moderate-to-Severe Alzheimer Disease: A Randomized Controlled Trial.
Reisberg B, Shao Y, Golomb J, Monteiro I, Torossian C, Boksay I, Shulman M, Heller S, Zhu Z, Atif A, Sidhu J, Vedvyas A, Kenowsky S. Reisberg B, et al. Among authors: monteiro i. Dement Geriatr Cogn Disord. 2017;43(1-2):100-117. doi: 10.1159/000455397. Epub 2017 Jan 26. Dement Geriatr Cogn Disord. 2017. PMID: 28122366 Free PMC article. Clinical Trial.
The BEHAVE-AD assessment system: a perspective, a commentary on new findings, and a historical review.
Reisberg B, Monteiro I, Torossian C, Auer S, Shulman MB, Ghimire S, Boksay I, Guillo BenArous F, Osorio R, Vengassery A, Imran S, Shaker H, Noor S, Naqvi S, Kenowsky S, Xu J. Reisberg B, et al. Among authors: monteiro i. Dement Geriatr Cogn Disord. 2014;38(1-2):89-146. doi: 10.1159/000357839. Epub 2014 Apr 7. Dement Geriatr Cogn Disord. 2014. PMID: 24714384 Free PMC article. Review.
Two Year Outcomes, Cognitive and Behavioral Markers of Decline in Healthy, Cognitively Normal Older Persons with Global Deterioration Scale Stage 2 (Subjective Cognitive Decline with Impairment).
Reisberg B, Torossian C, Shulman MB, Monteiro I, Boksay I, Golomb J, Guillo Benarous F, Ulysse A, Oo T, Vedvyas A, Rao JA, Marsh K, Kluger A, Sangha J, Hassan M, Alshalabi M, Arain F, Shaikh N, Buj M, Kenowsky S, Masurkar AV, Rabin L, Noroozian M, Sánchez-Saudinós MAB, Blesa R, Auer S, Zhang Y, de Leon M, Sadowski M, Wisniewski T, Gauthier S, Shao Y. Reisberg B, et al. Among authors: monteiro i. J Alzheimers Dis. 2019;67(2):685-705. doi: 10.3233/JAD-180341. J Alzheimers Dis. 2019. PMID: 30689585
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
264 results